Go back to trials list
Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)
Description
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
Trial Eligibility
Inclusion Criteria: * B-ALL blast cells expressing CD22 * Diagnosed with R/R B-ALL * Prior therapy must include at least one standard chemotherapy regimen and at least one salvage regimen Exclusion Criteria: -Prior cellular therapy or investigational cellular or gene therapy within 60 days prior to enrollment
Study Info
Organization
Cellectis S.A.
Primary Outcome
Incidence of AE/SAE/DLT [Safety and Tolerability]
Interventions
Locations Recruiting
University of California, Los Angeles (UCLA) - Medical Center
United States, California, Los Angeles
University of Colorado - Aurora Cancer Center
United States, Colorado, Aurora
Sarah Cannon - Colorado Blood Cancer Institute
United States, Colorado, Denver
University of Chicago
United States, Illinois, Chicago
Dana Farber Cancer Institute
United States, Massachusetts, Boston
Interested in joining this trial?
Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.
Get the latest thought leadership on your Chronic Neutrophilic Leukemia delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.